Please login to the form below

Not currently logged in
Email:
Password:

Testing for new Alzheimer's treatment

American pharma company Eli Lilly & Co announced on March 31 the start of a phase III clinical trial for a new Alzheimer's treatment.
American pharma company Eli Lilly & Co announced on March 31 the start of a phase III clinical trial for a new Alzheimer's treatment.

The new treatment, known as LY450139, will be tested in the IDENTITY (interrupting Alzheimer's Dementia by Evaluating Treatment of Amylold Pathology) trial.

Lilly claims that LY450139 could slow the onset of mild-to-moderate Alzheimer's disease and give patients preserved functionality and quality of life.

During the course of the double-blind, placebo-controlled study, 1,500 patients will take part in the trials in the US and 21 additional countries over the course of 21 months.

Dr Eric Siemers, medical director of Alzheimer's disease research for Lilly, said: "Alzheimer's is a devastating disease that destroys brain cells, affecting everything from a patient's memory to their work and social life. Currently available medications treat the symptoms of Alzheimer's disease but have not been shown to change its underlying progression, creating an urgent unmet medical need."

LY450139 is an investigational gamma secretase inhibitor and has been developed to counteract the degenerative progression of Alzheimer's by excreting an enzyme that creates a sticky protein.

Siemers said that Lilly hopes, "that LY450139 will represent an advance in the attempt to slow the progression of this fatal disease".

31st March 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Aptus Health

Aptus Health is dedicated to advancing health engagement. The company offers end-to-end digital health engagement solutions spanning all areas of...

Latest intelligence

Ali Frederic Ben-Amor
Tackling a formidable foe
Ali Frederic Ben-Amor tells how Merck is taking the fight to multiple sclerosis...
Geoff
Cancer care – the power of new technologies
With patient numbers set to soar, how can we make a difference?...
image 1
Redefining communications excellence
How to be heard in today’s multichannel, multistakeholder, multimedia world...

Infographics